Uncovering the Role of Public Funding in Patents and Licensing
This session will explore how public investment supports pharmaceutical innovation, and how transparency gaps—such as late disclosure of federal funding in patents and opaque university licensing practices—affect equitable access to medicines and public accountability.
Speakers
Luis Gil Abinader, Law and Policy Researcher – author of Late disclosures of federal funding in US patents, and UAEM North America Board Member
Ayolola Eni-Olotu, Universities Allied for Essential Medicines – author of Achieving equitable access to health technologies during a pandemic: Lessons learned from UK universities’ technology transfer practices & policies (2019–2023)
Moderated by: Jaume Vidal, Senior Policy Advisor, Health Action International
Opening remarks: Adrián Alonso Ruiz, Research and Advocacy Manager, Salud por Derecho
Join us to reflect on how greater openness in publicly funded research can strengthen equitable access to medicines and ensure that public investment truly serves the public interest.